跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-EMTRICITABINE/TENOFOVIR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-EMTRICITABINE/TENOFOVIR
Authorized
STANDARD
MINT-EMTRICITABINE/TENOFOVIR
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
60d36b26b9bcef14
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
60d36b26b9bcef14
Drug Approval Canada Name
MINT-EMTRICITABINE/TENOFOVIR
Product Name
MINT-EMTRICITABINE/TENOFOVIR
Status
Marketed
Status Date
2022-08-11
Original Market Date
2022-08-11
Din
02521547
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR03 TENOFOVIR DISOPROXIL AND EMTRICITABINE
Atc Name
j 05 ar 03
Aig Number
0251568001
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
EMTRICITABINE
200 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
60d36b26b9bcef14
Type
Standard
Back to Health Canada Approvals